• Clinical Trials - Lymphoma

    Study Objective Contact
    A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma [LCID Study Number: 2014-028] The purpose of this study is to test the effectiveness, safety and side effects of the ibrutinib for patients with marginal zone lymphoma. The study drug is believed to block a special protein that helps blood cancer cells live and grow. The study drug, Ibrutinib, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia or mantle cell lymphoma in patients who have received at least one prior treatment. It has not been approved for the type of cancer being being studied in this trial. Principal Investigator(s):
    Hande H. Tuncer, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon.
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab Chemotherapy [LCID Study Number: 2010-002] This study is being done to see if giving RAD001 can reduce the chance of relapse when it is given to patients with diffuse large B-cell lymphoma that is in complete remission. Rad001 is currently not approved by the FDA for use in this situation therefore, this treatment is considered experimental. Principal Investigator(s):
    Tarun Kewalramani, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon,
    Nancy M. Campbell, RN.